Overview
Practical Strategies for the Multispecialty Recognition and Treatment of Rare Immune-related Adverse Events
Deciphering Rare irAEs: A Go-to-Guide
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This immersive CME infographic provides a stepwise visual to support improved recognition and management of rare immune-related adverse events (irAEs) for patients on immune checkpoint inhibitors (ICPIs). The infographic synthesizes and visualizes data, guidelines and decision-making recommendations, as well as includes faculty commentary on strategies and practical resources that support personalized therapeutic management.
This activity is intended for oncologists, hematologists, gastroenterologists, cardiologists, internists, emergency medicine physicians and other specialists who care for oncology patients receiving immune checkpoint inhibitors.
Despite their substantial benefits for cancer treatment, immune checkpoint inhibitors (ICPis) are associated with a unique set of immune-related adverse events (irAEs) that are considerably different than those caused by traditional systemic chemotherapy. Because of their distinctive nature and variable kinetics, identification and management of irAEs requires vigilance about their onset and counseling patients about potential symptoms. Due to the wide range of potential irAEs, multidisciplinary management of irAEs is necessary to optimize clinical outcomes. Clinicians must know how to manage irAEs so that effective treatment can be continued. Accumulating clinical evidence on irAEs, advances in their management strategies and new literature create knowledge and practice gaps and pose a significant challenge for clinicians.
Upon completion of this activity, participants will be able to:
- Differentiate irAEs in patients receiving immune checkpoint inhibitor therapy from those associated with traditional treatment modalities
- Outline the occurrence, identification and management of rare irAEs
- Discuss strategies including recent guideline recommendations for monitoring and managing irAEs
- Integrate management of irAEs into the overall treatment of patients with cancer and improve communication between patients and their care team
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Bristol Myers Squibb.
John A. Thompson, MD
Medical Director, Phase I Clinical Trials Program
Seattle Cancer Care Alliance
Professor, Division of Oncology
University of Washington School of Medicine
Medical Director, Phase I Clinical Trials Program
Seattle Cancer Care Alliance
Professor, Division of Oncology
University of Washington School of Medicine
Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Assistant Professor of Nursing
Yale University School of Nursing
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Speakers Bureau: AstraZeneca, Bristol Myers Squibb, Genentech, Merck
The following have no relevant financial relationships:
John Thompson, MD
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: certain immunosuppressive drugs or regimens are discussed as a way to treat immune-related adverse events.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Katlyn Cooper at kcooper@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider approved by the California Board of Registered Nursing, Provider Number 17273 for 1.0 contact hour.
Completion of this activity including the pre, post, and follow-up assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.